MARX Biotech Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-66.7	-12.92	2.83	4.43
Depreciation & Amortization	9.27	4.57	1.95	-
Other Amortization	0.05	0.02	-	-
Loss (Gain) From Sale of Assets	-0.06	-	0.1	-
Loss (Gain) on Equity Investments	-	-	-	-4.97
Provision & Write-off of Bad Debts	9.14	2.89	0.99	-
Other Operating Activities	-0.62	-5.82	-2.04	-0.14
Change in Accounts Receivable	-81.6	-40.84	5.04	-
Change in Inventory	-19.44	-6.65	-2.98	-
Change in Accounts Payable	-11.75	3.13	-1.05	0.89
Change in Unearned Revenue	95.77	14.82	-	-
Change in Other Net Operating Assets	-1.3	26.65	6.59	0.11
Operating Cash Flow	-67.25	-14.14	11.44	0.31
Operating Cash Flow Growth	-	-	3566.35%	-
Capital Expenditures	-3.14	-1.04	-0.7	-
Cash Acquisitions	-72.39	-72.39	0.18	-
Sale (Purchase) of Intangibles	-3.29	-0.7	-	-
Other Investing Activities	-3.26	-3.97	-0.28	-0.05
Investing Cash Flow	-85.57	-78.09	-0.79	-0.05
Short-Term Debt Issued	-	-	10	-
Total Debt Issued	-	-	10	-
Short-Term Debt Repaid	-	-25.99	-	-
Long-Term Debt Repaid	-	-1.85	-1.7	-
Total Debt Repaid	-28.31	-27.85	-1.7	-
Net Debt Issued (Repaid)	-28.31	-27.85	8.3	-
Issuance of Common Stock	157.76	251.76	-	-
Common Dividends Paid	-6.59	-6.59	-7.35	-
Financing Cash Flow	122.87	217.33	0.95	-
Net Cash Flow	-29.95	125.1	11.6	0.27
Free Cash Flow	-70.38	-15.18	10.74	0.31
Free Cash Flow Growth	-	-	3343.27%	-
Free Cash Flow Margin	-15.85%	-5.24%	9.71%	-
Free Cash Flow Per Share	-0.14	-0.04	0.03	0.01
Cash Interest Paid	0.32	0.37	0.11	-
Cash Income Tax Paid	-	4.65	4.12	-
Levered Free Cash Flow	-99.7	-58.58	-38.72	-
Unlevered Free Cash Flow	-99.51	-58.34	-38.65	-
Change in Net Working Capital	61.3	50.64	40.46	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.